LianBio (LIANY): restructuring charge — LianBio to wind down operations, delist from Nasdaq, pay $4.80 special dividend

LianBio

Board approves wind-down; workforce reduction of ~50% (over 50 employees) in Q1 2024.
Voluntary delisting from Nasdaq; last trading day expected March 18, 2024; OTC trading planned.
Special cash dividend of $4.80 per ordinary share/ADS (~$528M aggregate); record date Feb 27, payable ~March 11.
Estimated wind-down costs ~$17.2M, primarily severance; full dissolution expected first half 2027.
Company will pursue sale of remaining pipeline assets; any profits to be distributed to shareholders.

item 2.05 item 3.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

LianBio announced a restructuring with charges of approximately $17.2 million in costs primarily related to employee severance and, in some cases, retention bonuses affecting over 50 full-time employees, or approximately 50% of the Company’s current employee base (reduction in force of over 50 full-time employees, or approximately 50% of the Company’s current employee base, in the f).

Type: restructuring
Charge: approximately $17.2 million in costs primarily related to employee severance and, in some cases, retention bonuses
Affected area: over 50 full-time employees, or approximately 50% of the Company’s current employee base
Headcount: reduction in force of over 50 full-time employees, or approximately 50% of the Company’s current employee base, in the f

Exact text from the filing

to meet its ongoing operational costs through funds retained after the special dividend. As a result of the wind down, the Company estimates that it will incur approximately $17.2 million in costs primarily related to employee severance and, in some cases, retention bonuses. The Company expects to record a significant portion of these charges in the first half of

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.